Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Bonodeau

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 6, 2004
[Partial breast irradiation: high dose rate peroperative brachytherapy technique using the MammoSite]Y Belkacémi, M P Chauvet, S Giard, et al.
British Journal of Cancer|April 1, 2010
Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard careN Penel, S Clisant, E Dansin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumorsF Barlési, C Balleyguier, B Besse, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 6, 2004
[Partial breast irradiation: high dose rate peroperative brachytherapy technique using the MammoSite]Y Belkacémi, M P Chauvet, S Giard, et al.
British Journal of Cancer|April 1, 2010
Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard careN Penel, S Clisant, E Dansin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumorsF Barlési, C Balleyguier, B Besse, et al.
Pageof 2